Why the study?
To develop a mortality risk prediction model in patients with acute heart failure using left ventricular function parameters with clinical factors.
Key points are not available for this paper at this time.
Population
4312 patients admitted for AHF from three tertiary centres
Comparison
Derivation cohort (1859 patients) vs validation cohort (1389 patients)
Design
Retrospective multicentre derivation and validation cohort study
Follow-up
32 (interquartile range 13-54) months
I need the paper’s actual verdict and results before writing the implication. Searching now.Found the paper. Pulling the full abstract and results next.May support GLS-based AHF risk estimates over EF; leaves open prospective validation before practice change.
AIMS: To develop a mortality risk prediction model in patients with acute heart failure (AHF), using left ventricular (LV) function parameters with clinical factors. METHODS AND RESULTS: In total, 4312 patients admitted for AHF were retrospectively identified from three tertiary centres, and echocardiographic parameters including LV ejection fraction (LV-EF) and LV global longitudinal strain (LV-GLS) were measured in a core laboratory. The full set of risk factors was available in 3248 patients. Using Cox proportional hazards model, we developed a mortality risk prediction model in 1859 patients from two centres (derivation cohort) and validated the model in 1389 patients from one centre (validation cohort). During 32 (interquartile range 13-54) months of follow-up, 1285 patients (39.6%) died. Significant predictors for mortality were age, diabetes, diastolic blood pressure, body mass index, natriuretic peptide, glomerular filtration rate, failure to prescribe beta-blockers, failure to prescribe renin-angiotensin system blockers, and LV-GLS; however, LV-EF was not a significant predictor. Final model including these predictors to estimate individual probabilities of mortality had C-statistics of 0.75 [95% confidence interval (CI) 0.73-0.78; P < 0.001] in the derivation cohort and 0.78 (95% CI 0.75-0.80; P < 0.001) in the validation cohort. The prediction model had good performance in both heart failure (HF) with reduced EF, HF with mid-range EF, and HF with preserved EF. CONCLUSION: We developed a mortality risk prediction model for patients with AHF incorporating LV-GLS as the LV function parameter, and other clinical factors. Our model provides an accurate prediction of mortality and may provide reliable risk stratification in AHF patients.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: